Cargando…
Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial
BACKGROUND: Several researches have recommended vitamin D possible health benefits on diabetic complications development, but a few number of studies have been accomplished on the molecular and cellular mechanisms. Certain cellular pathways modification and also some transcription factors activation...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814978/ https://www.ncbi.nlm.nih.gov/pubmed/31673295 http://dx.doi.org/10.1186/s13098-019-0479-x |
_version_ | 1783463103319506944 |
---|---|
author | Omidian, Mahsa Djalali, Mahmoud Javanbakht, Mohammad Hassan Eshraghian, Mohammad Reza Abshirini, Maryam Omidian, Parisa Alvandi, Ehsan Mahmoudi, Maryam |
author_facet | Omidian, Mahsa Djalali, Mahmoud Javanbakht, Mohammad Hassan Eshraghian, Mohammad Reza Abshirini, Maryam Omidian, Parisa Alvandi, Ehsan Mahmoudi, Maryam |
author_sort | Omidian, Mahsa |
collection | PubMed |
description | BACKGROUND: Several researches have recommended vitamin D possible health benefits on diabetic complications development, but a few number of studies have been accomplished on the molecular and cellular mechanisms. Certain cellular pathways modification and also some transcription factors activation may protect cells from hyperglycemia condition induced damages. This study purpose was to determine the vitamin D supplementation effect on some key factors [advanced glycation end products (AGEs) signaling pathway] that were involved in the diabetic complications occurrence and progression for type-2 diabetes participants. METHODOLOGY: 48 type-2 diabetic patients (T2DM) randomly divided into two groups (n = 24 per group), receiving: 100-µg vitamin D or placebo for 3 months. At this study beginning and the end, the receptor expression for advanced glycation end products (RAGE) and glyoxalase I (GLO1) enzyme from peripheral blood mononuclear cells (PBMCs) and AGEs and tumor necrosis factor-α (TNF-α) serum levels were measured by the use of real-time PCR and ELISA methods, respectively. RESULTS: This study results demonstrated that vitamin D supplementation could down-regulate RAGE mRNA [fold change = 0.72 in vitamin D vs. 0.95 in placebo) P = 0.001)]. In addition, no significant changes were observed for GLO1 enzyme expression (P = 0.06). This study results also indicated that vitamin D serum level significantly increased in vitamin D group (P < 0.001). Moreover, AGES and TNF-α serum levels significantly reduced in vitamin D group, but they were remained unchanged in the placebo group. CONCLUSION: In conclusion, vascular complications are more frequent in diabetic patients, and vitamin D treatment may prevent or delay the complications onset in these patients by AGEs serum level and RAGE gene expression reducing. Trial registration NCT03008057. Registered December 2016 |
format | Online Article Text |
id | pubmed-6814978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68149782019-10-31 Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial Omidian, Mahsa Djalali, Mahmoud Javanbakht, Mohammad Hassan Eshraghian, Mohammad Reza Abshirini, Maryam Omidian, Parisa Alvandi, Ehsan Mahmoudi, Maryam Diabetol Metab Syndr Research BACKGROUND: Several researches have recommended vitamin D possible health benefits on diabetic complications development, but a few number of studies have been accomplished on the molecular and cellular mechanisms. Certain cellular pathways modification and also some transcription factors activation may protect cells from hyperglycemia condition induced damages. This study purpose was to determine the vitamin D supplementation effect on some key factors [advanced glycation end products (AGEs) signaling pathway] that were involved in the diabetic complications occurrence and progression for type-2 diabetes participants. METHODOLOGY: 48 type-2 diabetic patients (T2DM) randomly divided into two groups (n = 24 per group), receiving: 100-µg vitamin D or placebo for 3 months. At this study beginning and the end, the receptor expression for advanced glycation end products (RAGE) and glyoxalase I (GLO1) enzyme from peripheral blood mononuclear cells (PBMCs) and AGEs and tumor necrosis factor-α (TNF-α) serum levels were measured by the use of real-time PCR and ELISA methods, respectively. RESULTS: This study results demonstrated that vitamin D supplementation could down-regulate RAGE mRNA [fold change = 0.72 in vitamin D vs. 0.95 in placebo) P = 0.001)]. In addition, no significant changes were observed for GLO1 enzyme expression (P = 0.06). This study results also indicated that vitamin D serum level significantly increased in vitamin D group (P < 0.001). Moreover, AGES and TNF-α serum levels significantly reduced in vitamin D group, but they were remained unchanged in the placebo group. CONCLUSION: In conclusion, vascular complications are more frequent in diabetic patients, and vitamin D treatment may prevent or delay the complications onset in these patients by AGEs serum level and RAGE gene expression reducing. Trial registration NCT03008057. Registered December 2016 BioMed Central 2019-10-26 /pmc/articles/PMC6814978/ /pubmed/31673295 http://dx.doi.org/10.1186/s13098-019-0479-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Omidian, Mahsa Djalali, Mahmoud Javanbakht, Mohammad Hassan Eshraghian, Mohammad Reza Abshirini, Maryam Omidian, Parisa Alvandi, Ehsan Mahmoudi, Maryam Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title | Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title_full | Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title_fullStr | Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title_full_unstemmed | Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title_short | Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial |
title_sort | effects of vitamin d supplementation on advanced glycation end products signaling pathway in t2dm patients: a randomized, placebo-controlled, double blind clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814978/ https://www.ncbi.nlm.nih.gov/pubmed/31673295 http://dx.doi.org/10.1186/s13098-019-0479-x |
work_keys_str_mv | AT omidianmahsa effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT djalalimahmoud effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT javanbakhtmohammadhassan effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT eshraghianmohammadreza effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT abshirinimaryam effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT omidianparisa effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT alvandiehsan effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial AT mahmoudimaryam effectsofvitamindsupplementationonadvancedglycationendproductssignalingpathwayint2dmpatientsarandomizedplacebocontrolleddoubleblindclinicaltrial |